SAB’s therapeutic shows promising results against Delta, other variants
Aug. 12, 2021
The treatment developed by Sioux Falls-based SAB Biotherapeutics for the virus that causes COVID-19 has shown “effective and potent” ability to neutralize multiple variants of concern, including the Delta and Lambda variants.
The data for the therapeutic, known as SAB-185, was published this week as part of a nonclinical study conducted by scientists at the FDA’s Center for Biologics Evaluation and Research and published in bioRxiv, the online life sciences archive for COVID-19 SARS-CoV-2 preprints.
“These encouraging data come at a critical time as the Delta variant is causing a surge of COVID-19 infections around the globe and public health experts are voicing concerns about emerging new variants such as Lambda and others yet to be identified,” Eddie Sullivan, co-founder, president and CEO of SAB Biotherapeutics, said in a statement.
“These in vitro data demonstrating the efficacy of SAB-185 against the Delta and Lambda variants were produced to provide new insights into antibody binding to the SARS-CoV-2 spike variants and as a result further bolster our confidence that SAB-185 has the potential to provide neutralization of current and future mutant SARS-CoV-2 strains. We look forward to working with our U.S. government collaborators to advance our COVID-19 program, with the goal of making SAB-185 available to patients as soon as possible once its clinical utility is confirmed.”
SAB-185 is a fully human, specifically targeted and broadly neutralizing polyclonal antibody therapeutic candidate. It is being assessed in a midstage trial in nonhospitalized patients with mild to moderate COVID-19 infections. It is the first polyclonal antibody therapeutic included in the ACTIV-2 master protocol, a study sponsored, funded and conducted by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health.
